Research Paper Volume 12, Issue 10 pp 8893—8912

Figure 1. lnc-LOC645166 is upregulated in breast cancer with adriamycin resistance. (A) Heat map of differentially expressed lncRNAs (the top 20 in upregulated lncRNAs and the top 20 in downregulated lncRNAs) between MCF-7 and MCF-7/ADR cells. (B) RT-qPCR analysis of top 10 upregulated lncRNAs between ADR-resistant breast cancer cell lines and their parent cell lines (n =3). (C) RT-qPCR analysis of five different expressed lncRNAs after treated with ADR for 24h and 48h in MCF-7 and 231 cell lines (n =3). (D) RT-qPCR analysis of lnc-LOC645166 in an independent set of breast tumors samples with good or poor responses to ADR therapy (n =3), R means resistant to ADR therapy, S means sensitive to ADR therapy. (E) Subcellular fractionation of MCF-7/ADR and 231/ADR cells to determine the cellular location of lnc-LOC645166. GAPDH acted as cytoplasmic marker and U6 acted as nuclear marker (n=3). Data are shown as means ± SD. *p < 0.05, **p < 0.01, ***p < 0.001.